

STUDY NUMBER: 2600030

Dear pioneer,

A study to the **treatment of cholestatic liver disease** will soon start at our research centre in Edegem.

Are you interested in participating and giving science a boost?

Hereby we would like to give you an overview of the study: duration of **± 26 weeks**.

In this cohort, the study medication will be administered **subcutaneously (under the skin)**.

A nutritional supplement will also be administered **orally (by mouth)**.

INCLUSION CRITERIA

▪ Last participation in other clinical study (final study):

Cohort 2 main: no later than **15JUL2026**

**Be careful: Final study visit of the previous study needs to be performed to be able to participate at screening.*

- Healthy males and non-childbearing potential females aged 18 to 55 years (inclusive)
- BMI: between 18,5 and 30.0 kg/m²
- Weight between 55.0 and 100.0 kg (inclusive)
- Non-smoker, or having stopped smoking at least 6 months before the first administration of the study medication
- No use of medication, vitamins, or homeopathic products (after consultation with the study physician, certain medications may be allowed during the study)
- Contraception:
 - **Non-childbearing potential females**
 - Postmenopausal* (no menstruation for at least 12 months)
 - **OR** undergone a hysterectomy (removal of the uterus)
 - **OR** undergone bilateral oophorectomy (removal of both ovaries)
 - **OR** undergone bilateral salpingectomy (removal of both fallopian tubes)
 - *Use of hormone replacement therapy is not permitted.*
 - **Men:** From screening until 90 days after the last administration of the study medication: Abstinence from heterosexual intercourse
 - **Use a condom during every sexual encounter**
 - If the partner is a woman of childbearing potential, advise her to use an additional effective contraceptive method until 90 days after the last administration of the study medication
 - **OR** undergone a vasectomy
 - **OR** remain abstinent from all sexual intercourse
 - **AND** no spermdonations
- No blood donations, blood loss (>480 mL), or blood transfusions within 30 days before the first administration of the study medication
- You will be required to comply with restrictions regarding physical activity and the consumption of caffeine-containing and alcoholic products
- You are not an employee of the sponsor, ProQR Therapeutics VIII B.V., nor an employee of SGS

■ **You are not eligible if you:**

- Have had your gallbladder removed
- Have Gilbert's syndrome
- Have veins that are difficult to access for blood sampling
- Have large tattoos, dermatological conditions, or significant skin abnormalities at the injection site (abdomen)
- Have previously participated in another cohort of Study 2600030

INTEREST IN PARTICIPATING

Registration for this study only indicates your interest and does not obligate you to participate, nor us to include you as a participant.

Thank you in advance for your interest and we hope to welcome you soon for study 2600030.

SGS CPU